The insulin receptor substrate-1: a biomarker for cancer?

Exp Cell Res. 2009 Mar 10;315(5):727-32. doi: 10.1016/j.yexcr.2008.09.017. Epub 2008 Oct 1.

Abstract

This review focuses on IRS-1 and the evidence of its role in cell transformation. The literature strongly suggests that IRS-1 should be considered a biomaker for cancers susceptible to IGF-IR targeting. In addition, I would like to propose that IRS-1 may have a more general role in cancer, and could be considered as a protein having the opposite effect of tumor suppressors, a sort of anti-p53 molecule.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Cell Transformation, Neoplastic / genetics
  • Drug Delivery Systems / methods
  • Humans
  • Insulin Receptor Substrate Proteins / genetics
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Receptor Substrate Proteins / physiology*
  • MicroRNAs / therapeutic use
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Binding

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Insulin Receptor Substrate Proteins
  • MicroRNAs
  • Phosphoinositide-3 Kinase Inhibitors